BOne marrow transfer to enhance ST-elevation infarct regeneration-2 - BOOST-2
Contribution To Literature:
The BOOST-2 trial failed to show that intracoronary injection of bone marrow cells (BMCs) improved left ventricular ejection fraction (LVEF).
The goal of the trial was to evaluate treatment with intracoronary injection of nucleated bone marrow derived cells compared with placebo among patients with ST-segment elevation myocardial infarction (STEMI).
Patients with large STEMI were randomized to low-dose BMC infusion (loBMCi; n = 38) versus high-dose BMC infusion (hiBMCi; n = 39) versus low-dose irradiated BMC infusion (loBMCi; n = 36) versus high-dose irradiated BMC infusion (hiBMCi; n = 38) versus placebo (n = 37).
- Total number of enrollees: 188
- Duration of follow-up: 6 months
- Mean patient age: 55 years
- Percentage female: 8%
- Percentage with diabetes: 23%
- Mean baseline LVEF: 45%
The primary outcome, change in LVEF at 6 months versus placebo, was 0.5% for loBMCi (p = 0.76), 1.0% for hiBMCi (p = 0.57), 1.2% for loBMCi (p = 0.55), and -0.2% for hiBMCi (p = 0.91).
For the secondary outcome, LV end-diastolic volume index was the same among all treated patients.
Among patients with large STEMI and mildly reduced LVEF, intracoronary injection of clonogenic or non-clonogenic BMCs did not improve LVEF at 6 months.
Wollert KC, Meyer GP, Müller-Ehmsen J, et al. Intracoronary autologous bone marrow cell transfer after myocardial infarction: the BOOST-2 randomised placebo-controlled clinical trial. Eur Heart J 2017;Apr 19:[Epub ahead of print].
< Back to Listings